Core Viewpoint - 甘李药业 has shown positive stock performance and financial growth, indicating a strong position in the biopharmaceutical industry, particularly in the production of insulin analogs and related products [1][2]. Financial Performance - As of September 30, 2025, 甘李药业 achieved a revenue of 30.47 billion yuan, representing a year-on-year growth of 35.73% [2]. - The net profit attributable to shareholders for the same period was 8.18 billion yuan, reflecting a year-on-year increase of 61.32% [2]. - The company has distributed a total of 16.12 billion yuan in dividends since its A-share listing, with 10.18 billion yuan distributed over the past three years [3]. Stock Market Activity - On January 14, 甘李药业's stock price increased by 2.01%, reaching 71.51 yuan per share, with a trading volume of 2.42 billion yuan and a turnover rate of 0.61% [1]. - The stock has risen by 5.05% year-to-date, with a 0.03% increase over the last five trading days, a 6.64% increase over the last 20 days, and a 2.79% increase over the last 60 days [1]. Shareholder Information - The number of shareholders as of September 30, 2025, was 94,700, an increase of 22.53% from the previous period [2]. - The average number of circulating shares per shareholder was 5,889, a decrease of 17.81% from the previous period [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 8.0042 million shares, an increase of 494,300 shares from the previous period [3].

Core Viewpoint - 甘李药业 has shown a positive financial performance with significant growth in revenue and net profit, indicating strong operational capabilities and market demand for its products [2][3]. Group 1: Stock Performance - On January 8, 甘李药业's stock price decreased by 2.04%, closing at 70.03 CNY per share, with a trading volume of 471 million CNY and a turnover rate of 1.19%, resulting in a total market capitalization of 41.83 billion CNY [1]. - Year-to-date, the stock price has increased by 2.88%, with a 4.58% rise over the last five trading days, a 10.42% increase over the last 20 days, and a 1.20% rise over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, 甘李药业 reported a revenue of 3.05 billion CNY, representing a year-on-year growth of 35.73%, and a net profit attributable to shareholders of 818 million CNY, which is a 61.32% increase compared to the previous year [2]. - Since its A-share listing, 甘李药业 has distributed a total of 1.61 billion CNY in dividends, with 1.02 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for 甘李药业 reached 94,700, an increase of 22.53% from the previous period, while the average number of circulating shares per person decreased by 17.81% to 5,889 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest with 8.0042 million shares, an increase of 494,300 shares from the previous period [3].

Core Viewpoint - Gannee Pharmaceutical experienced a stock price decline of 2.02% on December 18, with a current price of 65.45 CNY per share and a total market capitalization of 39.094 billion CNY. The company has seen a year-to-date stock price increase of 51.84% [1] Financial Performance - For the period from January to September 2025, Gannee Pharmaceutical reported a revenue of 3.047 billion CNY, representing a year-on-year growth of 35.73%. The net profit attributable to shareholders was 818 million CNY, reflecting a year-on-year increase of 61.32% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Gannee Pharmaceutical reached 94,700, an increase of 22.53% from the previous period. The average number of circulating shares per shareholder decreased by 17.81% to 5,889 shares [2] Dividend Distribution - Since its A-share listing, Gannee Pharmaceutical has distributed a total of 1.612 billion CNY in dividends, with 1.018 billion CNY distributed over the past three years [3] Major Shareholders - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 8.0042 million shares, an increase of 494,300 shares from the previous period. Other notable shareholders include Southern CSI 500 ETF and China Merchants National Bio-pharmaceutical Index A, with varying changes in their holdings [3]

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a year-to-date increase of 49.24% and a recent decline of 9.25% over the past 20 days, indicating volatility in its market performance [1][2]. Financial Performance - For the period from January to September 2025, 甘李药业 reported a revenue of 3.047 billion yuan, representing a year-on-year growth of 35.73%. The net profit attributable to shareholders was 818 million yuan, reflecting a significant increase of 61.32% compared to the previous year [2]. - The company has distributed a total of 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for 甘李药业 increased to 94,700, marking a rise of 22.53%. The average number of circulating shares per shareholder decreased by 17.81% to 5,889 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 8.0042 million shares, an increase of 494,300 shares from the previous period [3].

甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、生物医 药、医疗器械、多肽药、基金重仓等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 11月12日，甘李药业盘中上涨2.03%，截至09:50，报65.41元/股，成交1.78亿元，换手率0.49%，总市值 390.70亿元。 资金流向方面，主力资金净流入897.83万元，特大单买入652.78万元，占比3.68%，卖出325.78万元，占 比1.83%；大单买入4254.96万元，占比23.96%，卖出3684.13万元，占比20.75%。 甘李药业今年以来股价涨51.74%，近5个交易日涨1.92%，近20日跌7.73%，近60日涨7.21%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研 ...

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a year-to-date increase of 51.81% but a recent decline of 7.37% over the past five trading days [1] Financial Performance - As of September 30, 2025, 甘李药业 reported a revenue of 3.047 billion yuan, representing a year-on-year growth of 35.73% [2] - The net profit attributable to shareholders for the same period was 818 million yuan, showing a year-on-year increase of 61.32% [2] Shareholder Information - The number of shareholders increased by 22.53% to 94,700 as of September 30, 2025, while the average number of circulating shares per person decreased by 17.81% to 5,889 shares [2] - Cumulative cash dividends since the A-share listing amount to 1.612 billion yuan, with 1.018 billion yuan distributed over the past three years [3] Stock Performance and Trading Activity - As of November 4, 2025, 甘李药业's stock price was 65.44 yuan per share, with a market capitalization of 39.088 billion yuan [1] - The stock saw a net outflow of 26.8652 million yuan in principal funds, with significant selling pressure compared to buying [1] Business Overview - 甘李药业 specializes in the research, production, and sales of recombinant insulin analogs and related products, with 95.05% of its revenue coming from biopharmaceuticals [1] - The company is categorized under the pharmaceutical and biotechnology sector, focusing on innovative drugs and medical devices [1]

民生加银中证500指数增强发起式A（012926）基金经理为何江、周帅。 截至发稿，何江累计任职时间14年147天，现任基金资产总规模7.7亿元，任职期间最佳基金回报 60.55%， 任职期间最差基金回报-49.3%。 周帅累计任职时间2年125天，现任基金资产总规模3.51亿元，任职期间最佳基金回报36.01%， 任职期 间最差基金回报-10.13%。 10月14日，甘李药业跌3.99%，截至发稿，报69.22元/股，成交10.39亿元，换手率2.64%，总市值413.45 亿元。甘李药业股价已经连续7天下跌，区间累计跌幅13.06%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研发、生产和销售。 主营业务收入构成为：生物制品(原料药及制剂产品)95.05%，医疗器械及其他4.69%，特许权服务收入 0.14%，化药0.12%。 从基金十大重仓股角度 数据显示，民生加银基金旗下1只基金重仓甘李药业。民生加银中证500指数增强发起式A（012926）二 季度持有股数9800股 ...

Core Viewpoint - 甘李药业's stock has experienced fluctuations, with a notable increase of 71.97% year-to-date, but a recent decline of 6.90% over the past five trading days [1] Financial Performance - For the first half of 2025, 甘李药业 reported revenue of 2.067 billion yuan, a year-on-year increase of 57.18%, and a net profit attributable to shareholders of 604 million yuan, reflecting a growth of 101.96% [2] - Cumulative cash dividends since the company's A-share listing amount to 1.612 billion yuan, with 1.018 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for 甘李药业 increased to 77,300, up by 3.08%, while the average number of circulating shares per person decreased by 2.99% to 7,165 shares [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 7.5099 million shares, an increase of 174,800 shares from the previous period [3]

截至6月30日，甘李药业股东户数7.73万，较上期增加3.08%；人均流通股7165股，较上期减少2.99%。 2025年1月-6月，甘李药业实现营业收入20.67亿元，同比增长57.18%；归母净利润6.04亿元，同比增长 101.96%。 分红方面，甘李药业A股上市后累计派现16.12亿元。近三年，累计派现10.18亿元。 机构持仓方面，截止2025年6月30日，甘李药业十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股750.99万股，相比上期增加17.48万股。招商国证生物医药指数A（161726）位居第五大流 通股东，持股580.26万股，相比上期减少24.16万股。南方中证500ETF（510500）位居第六大流通股 东，持股536.87万股，相比上期增加69.27万股。创新药（159992）位居第八大流通股东，持股340.55万 股，为新进股东。南方阿尔法混合A（010357）位居第十大流通股东，持股264.69万股，为新进股东。 华安聚优精选混合（009714）退出十大流通股东之列。 责任编辑：小浪快报 9月23日，甘李药业盘中下跌2.01%，截至10:09，报72.12元/股，成 ...

Core Viewpoint - 甘李药业 has shown significant growth in stock price and financial performance, indicating strong market interest and operational success [1][2]. Financial Performance - As of June 30, 甘李药业 reported a revenue of 2.067 billion yuan, representing a year-on-year increase of 57.18% [2]. - The net profit attributable to shareholders reached 604 million yuan, marking a substantial growth of 101.96% compared to the previous year [2]. - Cumulatively, the company has distributed 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the last three years [3]. Stock Performance - The stock price of 甘李药业 increased by 69.72% year-to-date, with a recent 5-day increase of 0.32%, a 20-day increase of 19.00%, and a 60-day increase of 31.04% [1]. - The stock was trading at 73.16 yuan per share, with a market capitalization of 43.974 billion yuan as of September 5 [1]. Shareholder Structure - As of June 30, the number of shareholders increased to 77,300, up by 3.08% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.99% to 7,165 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 174,800 shares, and new entrants like Innovation Drug and Southern Alpha Mixed A [3].